Cerebral Physiology of NOWS
Key facts
- Who runs it
- Indiana University
- Where
- Indianapolis, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 46 people, planned
- Started
- 11 Aug 2026
- Expected to end
- Aug 2027
- Type of study
- Interventional, 3 groups
- Treatments tested
- FD-NIRS and DCS
- Record updated
- 19 August 2026
Who can take part
- Age
- Up to 1 day
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 20 criteriaShow less
Who can take part
- Infants with prenatal opioid exposure:
- Term born or near-term born (> 36w) infants
- Birth weight > 2 Kg
- History of prenatal opioid exposure; Control infants:
- Term born or near-term born (> 36w) infants
- Birth weight > 2 Kg; Mothers of infants with prenatal opioid exposure:
- greater or equal to 19 years of age
- Use of opioid substances during pregnancy - Defined as pregnant women who 1) are clinically diagnosed as having an opioid use disorder and are on methadone or buprenorphine maintenance program or 2) have a urine drug test positive for prescribed or illicit opioids; Mothers of control infants:
- greater than or equal to 19 years of age
Who cannot take part
- Any major congenital malformations or genetic syndromes
- Any major congenital malformations or genetic syndromes
- Any history of prenatal opioid exposure; Mothers of infants with prenatal opioid exposure:
- Major maternal illness during pregnancy or delivery that could impact infant cerebral perfusion as deemed by the study investigators (e.g. uterine rupture or preeclampsia); Mothers of control infants:
- Major maternal illness during pregnancy or delivery that could impact infant cerebral perfusion as deemed by the study investigators (e.g. uterine rupture or preeclampsia)
- Infants with prenatal opioid exposure:
- APGAR score at 5 min < 7
- Need for positive pressure ventilation in the delivery room; Control infants:
- APGAR score at 5 min < 7
- Need for positive pressure ventilation in the delivery room
- Tobacco, SSRI or any opioid use during pregnancy
Where in United States
- Indiana University/Riley Hospital for ChildrenIndianapolis, United StatesContact: Anna ThomasTaking people
About the trial
What the trial wants to find out
This study will use a new device to measure blood flow and oxygen levels in the brains of newborn infants who have had exposure to opioid medications in the womb, compared to newborns who have not had any exposure.
The 3 groups in the trial
- Prenatal opioid exposure (POE)Treatment being tested
A total of 20 newborns with prenatal opioid exposure will have daily bedside FD-NIRS/DCS measurements of cerebral oxygen saturation (SO₂), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO₂).
Treatment: FD-NIRS and DCS
- Healthy controlTreatment being tested
A total of 20 healthy age-matched newborns will have daily bedside FD-NIRS/DCS measurements of cerebral oxygen saturation (SO₂), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO₂).
Treatment: FD-NIRS and DCS
- Pharmacologic TreatmentTreatment being tested
A group of 6 newborns with POE who are treated pharmacologically for severe neonatal opioid withdrawal syndrome will have daily bedside FD-NIRS/DCS measurements of cerebral oxygen saturation (SO₂), cerebral blood flow (CBF), and cerebral metabolic rate of oxygen consumption (CMRO₂).
Treatment: FD-NIRS and DCS
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Detection of Neonatal Opioid Withdrawal Syndrome Using a Novel Cerebral Monitor.
- Record updated
- 19 August 2026